<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107727">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02094963</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2013-14</org_study_id>
    <nct_id>NCT02094963</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management</brief_title>
  <acronym>TICA KOREA</acronym>
  <official_title>A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and efficacy of Ticagrelor versus Clopidogrel
      in Asian/KOREAn patients with acute coronary syndromes intended for invasive management.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The time to first occurrence of any bleeding event</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety of Ticagrelor compared to Clopidogrel by measuring the time to first occurrence of any bleeding event(including major, minor bleedings)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to first occurrence of major bleeding event</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>by PLAtelet inhibition and patient Outcomes(PLATO) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first occurrence of minor bleeding event</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>by PLAtelet inhibition and patient Outcomes(PLATO) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first occurrence of major bleeding event or minor bleeding event</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first occurrence of major bleeding event</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first occurrence of minor bleeding event</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first occurrence of Bleeding Academic Research Consortium (BARC)  bleeding event from type 1 to type 5</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>By Bleeding Academic Research Consortium(BARC) Definition of Bleeding Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of first occurrence of discontinuation of study medication from any bleeding event</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non serious adverse events</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events following discontinuation of study medication</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>1year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first occurrence of death from vascular causes</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of death from vascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first occurrence of myocardial infarction</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first occurrence of stroke</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to occurrence of composite events</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time to occurrence of composite events(death from any cause, myocardial infarction, stroke)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to occurrence of death from any cause</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with net clinical benefit of any total bleeding and any event from the composite of death from vascular causes, Myocardial Infarction and stroke.</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>180mg loading and 90mg bid</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>600mg loading and 75mg qd</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 and more

          -  Index event of non-ST or ST segment elevation ACS

          -  Provision of signed informed consent

        Exclusion Criteria:

          -  Hypersensitivity to aspirin or ticagrelor

          -  Oral anticoagulation therapy that cannot be stopped

          -  Treated with thrombolysis within 24hrs

          -  Any other reason the investigator deems the subject to be unsuitable for the study
             e.g., Active malignant tumor

          -  Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow
             therapeutic index, or strong CYP3A inducers

          -  Any life-threatening condition with life expectancy less than 6months

          -  Mental condition (dementia, alcohol or drug abuse) which may be affect study
             compliance or prevent understanding of the aims, investigational procedures or
             possible consequences of the study

          -  High risk due to malignant hypertension

          -  The conditions associated with increased risk of bradycardiac events

          -  Subjects with severe liver disease

          -  Subjects requiring dialysis

          -  Increased bleeding risk

          -  History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major
             surgical procedure within 30days

          -  Thrombocytopenia or leukopenia

          -  Positive pregnancy test or is known to be pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Cheonan</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Dae-jeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Si-Wan Choi, MD</last_name>
      <email>siwanc@cnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Si-wan Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongguk University Gyeongju Hospital</name>
      <address>
        <city>Gyeongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deuk-young Nah, MD</last_name>
      <email>ptca@dongguk.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Deuk-young Nah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sung-yun Lee, MD</last_name>
      <email>im2pci@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sung-yun Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChonBuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A Medical Center</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 23, 2014</lastchanged_date>
  <firstreceived_date>March 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>acute coronary syndrome</keyword>
  <keyword>coronary disease</keyword>
  <keyword>coronary artery disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
